MarketPeel
Insider Trading Intelligence
BL

Bain Capital Life Sciences Fund Iv, L.p.

OLMA
10% OWNER · OLEMA PHARMACEUTICALS, INC. · CIK 0001996979
FILING MIX · LIFETIME63%/37%
BUYS
5
SELLS
3
TOTAL VALUE
$26.73M
COMPANIES
2
ACTIVE SINCE
Jan 2025
HOLDINGS NOW
20,375,000
AVG SELL PX
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Bain Capital Life Sciences Fund Iv, L.p., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%-4.24%+0.73%-4.97%-4.97%
14d2+50.00%+0.37%+2.09%-1.73%-1.73%
30d2+0.00%-10.66%+1.91%-2.96%-2.96%
60d2+0.00%-23.88%+0.23%-24.11%-24.11%
90d2(1 pending)+0.00%-46.78%-15.53%-31.26%-31.26%
180d2(1 pending)+0.00%-22.61%+5.61%-28.22%-28.22%
1y2(1 pending)+100.00%+344.70%+17.32%+327.38%+327.38%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OLMA · 3,500,000 shares · as of Jan 10, 2025
01,950,0003,900,0005,850,0007,800,000SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2025
2026
2026
FLOW · 5 buys / 3 sellsCOVERAGE · 6 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KLRA
KAILERA THERAPEUTICS, INC.
SALE
16,875,0000Apr 20, 2026Apr 20, 2026View →
KLRA
KAILERA THERAPEUTICS, INC.
PURCHASE
4,145,76821,020,768Apr 20, 2026Apr 20, 2026View →
KLRA
KAILERA THERAPEUTICS, INC.
SALE
4,145,7680Apr 20, 2026Apr 20, 2026View →
KLRA
KAILERA THERAPEUTICS, INC.
PURCHASE
1,562,500$16.00$25.00M22,583,268Apr 20, 2026Apr 20, 2026View →
KLRA
KAILERA THERAPEUTICS, INC.
PURCHASE
16,875,00016,875,000Apr 20, 2026Apr 20, 2026View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
3,500,0004,300,000Jan 10, 2025Jan 13, 2025View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
3,500,0003,500,000Jan 10, 2025Jan 13, 2025View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
300,000$5.76$1.73M7,800,000Jan 8, 2025Jan 13, 2025View →
Other insiders · OLMA
Loading peer insiders…
About this filer
CIK 0001996979
ROLE
10% Owner
PRIMARY
OLMA
COMPANIES
2
ACTIVE SINCE
Jan 2025
MARKETPEEL · /INSIDER/0001996979DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback